(300 WORDS MAX.) Alzheimer's disease (AD) is an irreversible neurological disorder that leads to the progressive loss of memory, emotional and behavioral problems, and ultimately death. AD is devastating to the patients, their families and caregivers. An estimated 5.4 million Americans currently have AD, and the continuing rise in this population will certainly lead to catastrophic economic consequences if effective treatments are not quickly found. While AD is characterized by the hallmarks of beta-amyloid deposits and neurofibrillary tangles, it is also characterized by an inflammatory component that appears critical to AD progression. Thus, it is anticipated that suppressing the inflammation that is critical to the development of the AD should be able to reduce the progress of AD. In the clinical trial proposed here, patients with mild AD will be treated with Longeveron-produced mesenchymal stem cells (LMSCs), a type of stem cell with powerful anti-inflammatory and pro-regenerative properties. It is hoped that LMSCs will be able to impede and/or reverse the progression of dementia in these patients, thus providing a much needed effective therapy for AD patients.